Skip to content
value.today

ARCA biopharma, Inc.

Total raised
$5 M
1 round on record
Latest round
$5 M
Dec 2011
First round on record
Dec 2011
Today
Went public
See the company page

ARCA biopharma, Inc. is listed today as Oruka Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.

Funding rounds of ARCA biopharma, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2015$52 MPrivate placement after listing$50 to $250 million

ARCA biopharma, Inc.: Private sale, Jun 2015

Investors in this round

14 investors had bought by the notice of Jun 25, 2015: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for ARCA biopharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$52 M of $52 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,590,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian L. Selby · Executive Officer
  • Christopher D. Ozeroff · Executive Officer
  • Michael R. Bristow · Executive Officer, Director
  • Thomas A. Keuer · Executive Officer
  • Dan J. Mitchell · Director
  • Linda S. Grais · Director
  • Raymond L. Woosley · Director
  • Robert E. Conway · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • MTS Securities, LLC (CRD 104059) · New York, New YorkSold in CA, MA, MD, NC, NY

Remarks in the notice

  • On the amounts: “The Total Offering Amount and Total Amount Sold include the aggregate exercise price of certain warrants to purchase shares of Common Stock of the Issuer.”

Signed by Brian L. Selby, Vice President, Finance. Source: SEC Form D, newest notice filed Jun 25, 2015. Read the notice at the SEC.

equity, optionsSEC
Jun 2013$1 MPrivate placement after listingUnder $2 million

ARCA biopharma, Inc.: Private sale, Jun 2013

Investors in this round

2 investors had bought by the notice of Jun 17, 2013: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for ARCA biopharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher D. Ozeroff · Executive Officer
  • Michael R. Bristow · Executive Officer, Director
  • Patrick M. Wheeler · Executive Officer
  • Jean-Francois D. Formela · Director
  • John L. Zabriskie · Director
  • Linda D. Grais · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Assumes the exercise of warrants to purchase 625,000 shares of the Issuer's common stock at an exercise price of $2.00 per share.”

Signed by Michael R. Bristow, President & CEO. Source: SEC Form D, newest notice filed Jun 17, 2013. Read the notice at the SEC.

optionsSEC
Jan 2013$1 MPrivate placement after listingUnder $2 million

ARCA biopharma, Inc.: Private sale, Jan 2013

Investors in this round

5 investors had bought by the notice of Feb 1, 2013: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for ARCA biopharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$70,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher D. Ozeroff · Executive Officer
  • Michael R. Bristow · Executive Officer, Director
  • Patrick M. Wheeler · Executive Officer
  • Burton E. Sobel · Director
  • Jean-Francois D. Formela · Director
  • John L. Zabriskie · Director
  • Linda D. Grais · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Dawson James Securities, Inc. (CRD 130645) · broker-dealer Monique Maclaren · Boca Raton, FloridaSold in all US states
  • Dawson James Securities, Inc. (CRD 130645) · broker-dealer Joseph E. Balagot (CRD 4007591) · Santa Clara, CaliforniaSold in all US states

Remarks in the notice

  • On fees: “Dawson James Securities Inc., as placement agent, received a fee for its services in the transaction equal to 6% of the gross financing proceeds received by ARCA. ARCA issued 363,558 warrants to Dawson, and paid Dawson $10,000 in expenses reimbursement.”
  • On the use of proceeds: “A portion of the funds will be used for operating expenses which may include payroll payments to the executive officers.”

Signed by Patrick M. Wheeler, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 1, 2013. Read the notice at the SEC.

equity, optionsSEC
Dec 2011$5 MNo. 1$2 to $10 million

ARCA biopharma, Inc.: Raise no. 1, Dec 2011

Investors in this round

6 investors had bought by the notice of Jan 5, 2012: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for ARCA biopharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$97,500
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher D. Ozeroff · Executive Officer
  • Michael R. Bristow · Executive Officer, Director
  • Patrick M. Wheeler · Executive Officer
  • Burton E. Sobel · Director
  • Jean-Francois B. Formela · Director
  • John L. Zabriskie · Director
  • Linda B. Grais · Director
  • Richard B. Brewer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Roth Capital Partners LLC (CRD 15407) · broker-dealer Roth Capital Partners LLC (CRD 15407) · Newport Beach, CaliforniaSold in CA, IL, NY

Signed by Patrick M. Wheeler, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 5, 2012. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • ARCA biopharma, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2015).

    SEC Form D · Jun 2015

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jun 2015

That is all the official record says: ARCA biopharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of ARCA biopharma, Inc. are on record.

Investors#

3 named in official filings. Open an investor to see everything it has backed.

Investors in ARCA biopharma, Inc.
InvestorKindAmountRoundRoleSource
Fairmount Funds Management LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner, director (Form 3, 2024)SEC Form 3
Fairmount Healthcare Co-Invest III L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner, director (Form 3, 2024)SEC Form 3
Fairmount Healthcare Fund II L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner, director (Form 3, 2024)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 6 investors.

Largest shareholders today

Institutions holding Oruka Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by ARCA biopharma, Inc.
NameRoleNamed in
Brian L. SelbyExecutive officerJun 2015
Christopher D. OzeroffExecutive officerJun 2015
Michael R. BristowExecutive officerJun 2015
Thomas A. KeuerExecutive officerJun 2015
Patrick M. WheelerExecutive officerJun 2013
Dan J. MitchellDirectorJun 2015
Linda S. GraisDirectorJun 2015
Michael R. BristowDirectorJun 2015
Raymond L. WoosleyDirectorJun 2015
Robert E. ConwayDirectorJun 2015
Jean-Francois D. FormelaDirectorJun 2013
John L. ZabriskieDirectorJun 2013
Linda D. GraisDirectorJun 2013
Burton E. SobelDirectorFeb 2013
Jean-Francois B. FormelaDirectorJan 2012
Linda B. GraisDirectorJan 2012
Richard B. BrewerDirectorJan 2012

Went public since 2012. Its SEC number is that of a company listed on a stock exchange.